RESEARCH ARTICLE

Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression

Jiajia Zhang1,2,3†, Feize Li4†, Yuzhen Yin1,2,1†, Ning Liu4, Mengqin Zhu1,2, Han Zhang1,2, Weihao Liu4, Mengdie Yang1,2, Shanshan Qin1,2, Xin Fan1,2, Yuanyou Yang4*, Kun Zhang2,3* and Fei Yu1,2*

Abstract

Background: Astatine-211 is an α-emitter with high-energy α-ray and high cytotoxicity for cancer cells. However, the targeted alpha therapy (TAT) also suffers from insufficient systematic immune activation, resulting in tumor metastasis and relapse. Combined immune checkpoint blockade (ICB) with chemodynamic therapy (CDT) could boost antitumor immunity, which may magnify the immune responses of TAT. This study aims to discourage tumor metastasis and relapse by tri-model TAT-CDT-ICB strategy.

Methods: We successfully designed Mn-based radioimmunotherapy promoters (211At-ATE-MnO2-BSA), which are consisting of 211At, MnO2 and bovine serum albumin (BSA). The efficacy of 211At-ATE-MnO2-BSA was studied as mono-therapy or in combination with anti-PD-L1 in both metastatic and relapse models. The immune effects of radioimmunotherapy promoters on cytotoxic T lymphocytes and dendritic cells (DCs) were analyzed by flow cytometry. Enzyme-linked immunosorbent assay and immunofluorescence were used to explore the underlying mechanism.

Results: Such radioimmunotherapy promoters could not only enhance the therapeutic outcomes of TAT and CDT, but also induce robust anti-cancer immune activity by activating dendritic cells. More intriguingly, 211At-ATE-MnO2-BSA could effectively suppress the growths of primary tumors and distant tumors when combined with immune checkpoint inhibitors.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: The tri-model TAT-CDT-ICB strategy provides a long-term immunological memory, which can protect against tumor rechallenge after eliminating original tumors. Therefore, this work presents a novel approach for TAT-CDT-ICB tri-modal cancer therapy with repressed metastasis and relapse in clinics.

Keywords: Targeted alpha therapy, Immune activation, Chemodynamic therapy, Immune checkpoint blockade, Tumor relapse inhibition

Introduction
Radiotherapy (RT) includes internal radiotherapy (IRT) and external-beam radiotherapy (EBRT), both of which highlight ionizing radiation beams such as X-ray, β-ray, or α-ray directly kill cancer cells and boost antitumor immunity [1–3]. IRT has attracted increasing interest since it features high safety and efficacy, and has been widely used to activate antitumor immunity [3]. However, the current nuclides predominantly focused on β-particles, where β-particles inevitably pose physiological toxicity and radiation resistance due to the presence of a hypoxic tumor microenvironment [4, 5]. Compared to β-particles, α-particles are much preferable because they have high linear energy transfer (>50 keV/μm), which determined that they can lead to more DNA double-strand injures and relative biological efficiency within a much lower radiation dose. More importantly, the α-particle-based IRT is independent on cellular oxygenation [6, 7]. Unfortunately, medically-useful α-emitters remain inaccessible and the activated immune responses are insufficient, hampering their clinical expansion. Chemodynamic therapy (CDT) is a promising therapy by utilizing Fenton or Fenton-like reactions to modulate the immunogenic tumor microenvironment [8]. Previous study showed that Fe-based CDT could induce immunogenic cell death and promote the release of tumor-associated antigens (TAAs), furtherly boosting the systemic immune responses [9]. However, single CDT strategy alone is not sufficient to activate immune responses for suppressing tumor metastasis and recurrence, which usually needs combined therapy such as immunotherapy, radiotherapy, etc. Tumor metastasis and recurrence caused 90% of patient deaths in clinic practices [10, 11], and immunotherapy was identified as the most promising mean to eradicate tumors and repress tumor metastasis. Immunotherapy can stimulate immune responses to assault distant tumors and even induce robust immune memory effects [4]. However, the inherently immunosuppressive tumor microenvironment (ITM), immune escape, and immune desert render malignancy into a cold one featuring low mutation burdens, low neoantigen burden and inadequate infiltrated effector T cells [12]. Typically, although immune checkpoint blocking (ICB) therapy has made significant progress in clinics [13–15], only less than 20% of cancer patients could benefit from ICB due to the ITM [16]. Regarding this, immunotherapy synergy with other therapeutic approaches was highlighted to activate systematic immune responses and mitigate ITM [17, 18]. Importantly, the marriage of alpha radionuclide-based IRT with ICB is also expected to arouse potent immune responses and repress tumor metastasis.

In this report, 211At-tethered radioimmunotherapy promoters were established to simultaneously achieve IRT and chemodynamic therapy, wherein bovine serum albumin (BSA)-coated MnO2 (MnO2-BSA) nanoparticles were firstly yielded via a well-established protein biomimetic mineralization method [19]. 211At as the most suitable candidate for targeted alpha therapy (TAT) could be conjugated to MnO2-BSA nanoparticles via condensation reaction by the bifunctional linker, i.e., N-succinimidyl 3-trimethylstannyl-benzoate (ATE). The short half-life of 211At determines that 211At will not cause medical problems that other α-emitting radionuclides such as 223Ra and 225Ac suffer from [20, 21]. Besides serving as carriers, MnO2-BSA enables chemodynamic therapy process to generate •OH, which has been documented to directly kill tumor cells and simultaneously enhance ICB. It has been documented that reactive oxygen species (ROS) as well as their killing effects could trigger more tumor-associated antigens release, modulate ITM and activate systematic immune responses [9, 22–24]. In light of it, the combined therapy consisting of CDT and TAT in 211At-ATE-MnO2-BSA could not only extraordinarily ameliorate the tumor progression through TAT and CDT both in vitro and vivo, but also could elicit the robust antitumor immune responses and increase the infiltration of cytotoxic T lymphocytes (CTLs), further repressing tumor cells. Especially after integrating with anti-PD-L1-enabled ICB, the tri-modal TAT/CDT/ICB combined therapy in 211At-ATE-MnO2-BSA radioimmunotherapy promotes effectively ablated the primary tumor, and more importantly gave rise to long-term immunological memory effects to inhibit distant metastasized ones. Taken all together, this study explored a novel strategy to establish a TME-activated therapy based on 211At-ATE-MnO2-BSA, which achieved synergistic TAT/CDT/ICB with remarkable efficiency (Scheme 1).

Scheme 1
Methods

Materials

The radioisotope $^{211}$At was produced via $^{209}$Bi ($\alpha$, 2n) $^{211}$At reaction through CS-30 cyclotron according to the published protocol [25]. Bovine serum albumin (BSA), Manganese chloride tetrahydrate (MnCl$_2$·4H$_2$O), and sodium hydroxide (NaOH) were from Sigma-Aldrich. Roswell park memorial institute (RPMI) 1640 medium, penicillin-streptomycin, and fetal bovine serum (FBS) were obtained from Gbico. The cell counting kit-8 (CCK-8) was obtained from Biosharp. The anti-mouse PD-L1 antibody was obtained from BioXcell (clone:10F.9G2). APC anti-mouse CD45(Catalog: 103111), FITC anti-mouse CD3 (Catalog: 100203), BV421™ anti mouse CD4(Catalog: 100437), APC/Cy7 anti-mouse CD8a (Catalog: 100714), PE anti-mouse FOXP3 (Catalog: 126403), FITC anti-mouse CD11c (Catalog: 117305), PE anti-mouse CD86 (Catalog:105007), APC anti-mouse CD80 (Catalog: 104713), PE/Cy7 anti-mouse CD45 (Catalog: 103113), PE anti-mouse CD44(Catalog:103023) and BV421-anti-mouse CD62L (Catalog: 104435) antibodies were obtained from Biolegend. Tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) ELISA kit was purchased from Multisciences Biotech, Co., Ltd.

Synthesis of MnO$_2$-BSA nanoparticles

The MnO$_2$-BSA were prepared following a BSA-constrained biomineralization strategy. Briefly, a BSA solution (125 mg, 50 mL) and an aqueous MnCl$_2$·4H$_2$O solution (0.1 M, 250 μL) were mixed and stirred at 37 °C for 3 min. Subsequently, 500 μL NaOH solution (1 M) was introduced to adjust the pH value to 11 ~ 12. After 6 h of stirring at 37 °C, the brown mixture was collected and dialyzed (MWCO $= 8000 ~ 14,000$ Da) with deionized water for 24 h to remove redundant Mn$^{2+}$. Finally, the powder was collected after lyophilization and stored at 4 °C for further use.

Characterization of MnO$_2$-BSA

Transmission electron microscope (Tecnai G2 F20 S-TWIN, Netherlands) was used to observe the morphology and size of the MnO$_2$-BSA. The size distribution of MnO$_2$-BSA was monitored by dynamic light scattering (DLS) using a Malvern Zetasizer Nano ZS instrument. The UV-vis absorption spectrum of MnO$_2$-BSA were measured by an UV-vis spectrophotometer (UV-2450, Shimadzu, Japan). Elemental mappings and energy dispersive X-ray spectroscopy (EDS) were acquired from FEI Talos F200X. X-ray photoelectron spectroscopy
(XPS) was used to analyze the valence state of Mn in MnO₂-BSA by Thermo Kalpa. The Mn content were quantified on the inductively coupled plasma-optical emission spectrometry (ICP-OES, Agilent 730).

The generation of ·OH with MnO₂-BSA NPs
To measure the generation of ·OH, the MnO₂-BSA NPs were mixed with GSH solution (10 mM) at different pH (7.4, 6.5 and 5.0). Subsequently, 10 μg/mL methylene blue (MB), different concentration H₂O₂ (1 mM, 4 mM, 8 mM) were mixed. After different time incubation, the ·OH generation ability was evaluated by MB degradation via the change in absorbance. In addition, an electron paramagnetic resonance (EPR) spectrometer was also used to detect the existence of ·OH.

Radioisotope labeling and labeling stability assay
N-succinimidyld 3-trimethylstannyl benzoate (ATE) (dissolved in DMSO) and MnO₂-BSA (dissolved in PH 9 Na₂CO₃ buffer) were mixed and incubated at room temperature for 30 min. Subsequently, the product was purified using an Amicon filters (MWCO 30kDa) to remove excess ATE. Subsequently, MnO₂-BSA, N-iodosuccinimide (NIS, 3 mg/mL in MeOH) and ²¹¹At (500 μCi) solution was mixed and allowed to stand for 30 min at room temperature. The reacted solution was purified using an Amicon filters (MWCO = 30kDa) to remove redundant ²¹¹At till no detachable radioactivity in the filtrate solution [26]. The in vitro stability of ²¹¹At-MnO₂-BSA was determined with paper chromatography through Whatman No.1 filter paper. Briefly, ²¹¹At-ATE-MnO₂-BSA (10 μL) was added to 100 μL of PBS (PH = 7.4) or 10% FBS and incubated at 37°C for 0 h, 5 h, and 24 h. At each time point, 1 μL of mixture was placed Whatman No.1 filter paper and was allowed to be evaporated spontaneously. Then, we put it into the developing tank with developing solvent to separate ²¹¹At-ATE-MnO₂-BSA from free ²¹¹At. When the chromatography liquid reaches the front, the filter paper was taken out and dried at room temperature. Finally, we cut the paper into 1 cm sections, and put the paper pieces into the test tube in turn. The radioactivity count of each paper was measured in the counter.

Cell cytotoxicity assay
The breast cancer 4T1 cells and colorectal cancer CT26 cells were originally obtained from the Shanghai Institute of Cells, Chinese Academy of Sciences, and cultured under recommended conditions. 4T1 cells and CT26 cells were pre-seeded in a 96-well plate with a density of 5 × 10⁴ cells per well overnight to allow the attachment of cells. Free ²¹¹At and ²¹¹At-ATE-MnO₂-BSA were co-cultured with 4T1 cells and CT26 cells at different radioactivity for 12 h. Subsequently, the cell viability was measured according to the CCK-8 assay kit protocol at the wavelength of 450 nm.

Immunofluorescence staining of γ-H2AX
Breast cancer 4T1 cells were seeded in 6-well plates with densities of 3 × 10⁴ cells per dish. After 24 h, cells were treated with MnO₂-BSA, free ²¹¹At, and ²¹¹At-ATE-MnO₂-BSA for 12 h. Then, the cells were dealt with γ-H2AX and DAPI and imaged by a fluorescence microscope (Olympus).

Comet assay
The 4T1 cells were seeded into 6-well plates. After the cells were adhered onto wall, different treatments were conducted as follows, e.g., (1) control, (2) MnO₂-BSA, (3) ²¹¹At, (4) ²¹¹At-ATE-MnO₂-BSA. After 12 h, the cells of each group were collected by centrifugation and washed with PBS to obtain the cell suspension. 10 μL of cell suspension was taken out and mixed with 100 μL of comet agarose. The mixture was dripped onto the 6-well comet slide. Subsequently, lysis, unrotation, and electrophoresis were performed in turn. After electrophoresis, the cells were stained with propidium iodide for 10 min and washed twice. Finally, the degree of DNA damage in cells was photographed by fluorescence microscopy.

Tumor models and efficacy evaluation
All animal experiments were approved by Animal Welfare Ethics Committee of Shanghai Tenth People’s Hospital with an approval number (ID: SHDSYY-2021-3429-0746). Female BALB/c mice aged 6–8 weeks were purchased from Chengdu Dossy Experimental Animals Co., Ltd. To construct the tumor-bearing mice model, 1 × 10⁶ 4T1 cells and CT26 cells were subcutaneously injected into the back of BALB/c mice. Mice were administrated with potassium iodide solution (1%) for 7 days to saturate the thyroid and decrease the uptake of the thyroid. To investigate bio-distribution of ²¹¹At-ATE-MnO₂-BSA, 4T1 tumor-bearing mice and CT26 tumor-bearing mice were intratumorally injected with ²¹¹At-ATE-MnO₂-BSA at radioactive dose of 15 micro Curie (μCi). Then mice were sacrificed at 12 h, tumors and organs were collected and weighed, and the radioactivity was tested. For subcutaneous tumors inhibition, mice bearing subcutaneous 4T1 tumors were randomly divided into four groups including control, MnO₂-BSA (i.t., 90 μM), free ²¹¹At (i.t., 15 μCi), and ²¹¹At-ATE-MnO₂-BSA (i.t.,15 μCi) respectively. The tumor and body weight were measured every second day. And the tumor volume was calculated using the following equation: volume = width² × length/2. The 4T1 tumors in each group were harvested on day 14 post treatment to perform the H&E staining and TUNEL staining.
For distant tumors inhibition, 4 T1 cells and CT26 cells were inoculated onto both flanks of every BALB/c mouse back. The left injected with $1 \times 10^6$ cells were regarded as the primary tumor and the right injected with $5 \times 10^5$ cells were set as the distant tumor. Mice were administrated with 1% KI solution for 7 days before the treatment and were divided into four groups randomly, including (1) control, (2) anti-PD-L1, (3) $^{211}$At-ATE-MnO$_2$-BSA, (4) $^{211}$At-ATE-MnO$_2$-BSA + anti-PD-L1. For the primary tumor, $^{211}$At-ATE-MnO$_2$-BSA was intratumorally injected into animals at the dose of 15 μCi. Anti-PD-L1 antibodies were intraperitoneally injected with anti-PD-L1 antibodies (75 μg per mouse) at 1, 3 and 5 days.

The growth of primary/distant tumors and body weight was monitored every two days. To explore the antitumor immune effect, CT26 tumors were collected and digested to conduct single cell suspensions. The cell suspensions were stained with the corresponding antibodies to identify the activated T cells (FITC-anti-mouse CD3 and APC-Cy7-anti-mouse CD8 antibodies) and Treg cells (BV421-anti-mouse CD4 and PE-anti-mouse Foxp3 antibodies), finally analyzed by flow cytometry. In addition, interferon gamma (IFN-γ, Multi sciences) and tumor necrosis factor alpha (TNF-α, Multi sciences) in addition, interferon gamma (IFN-γ, Multi sciences) and tumor necrosis factor alpha (TNF-α, Multi sciences) in the serum were analyzed by ELISA assay. To study the tumor survival of mice. At the end of this experiment, the organs including lungs, heart, liver, spleen, and kidneys were harvested for HE staining using a standard protocol and finally observed under a microscope.

**Ex vivo analysis of dendritic cells**

To study in vivo DCs stimulation of $^{211}$At-ATE-MnO$_2$-BSA, tumors were obtained from CT26 tumor-bearing mice after 3 days post-treatments including control, MnO$_2$-BSA (i.t., 90 μM), free $^{211}$At (i.t., 15 μCi), and $^{211}$At-ATE-MnO$_2$-BSA (i.t., 15 μCi) to acquire single cell suspension. After that, the DCs were stained FITC anti-mouse CD11c (Catalog: 117305), PE-anti-mouse CD86 (Catalog: 105007), APC anti-mouse CD80 (Catalog: 104713) antibodies for flow cytometry assay.

**In vivo biosafety evaluation**

The blood samples were collected for liver function and kidney function analysis. At the same time, the major organ including lungs, heart, liver, spleen, and kidneys were harvested for HE staining using a standard protocol and finally observed under a microscope.

**Statistical analysis**

The statistical analysis was carried out with Origin2019 and Graphpad prism8. All experimental data were expressed in this manuscript as mean ± standard deviation. The statistical significance of the differences was determined by t-test. The asterisks indicate significant differences (* means $P<0.05$, ** means $P<0.01$, *** means $P<0.001$).

**Results**

**Synthesis and characterization of MnO$_2$-BSA NPs**

The MnO$_2$-BSA radioimmunotherapy promoters were synthesized via an environment-friendly bio-mimetic mineralization method, and the obtained MnO$_2$-BSA nanoparticles show relatively uniform sizes and well-defined shapes with an average diameter of ~20 nm (Fig. 1a), which is further verified by dynamic light scattering (DLS). The hydrodynamic diameter of MnO$_2$-BSA is around 20 nm (polydispersity index, PDI = 0.342) and with a negative surface charge (~24.2 mV) (Fig. 1b). The MnO$_2$-BSA nanoparticles show an evident characteristic absorbance peak within 200 nm–300 nm, indicating the successful synthesis (Fig. 1c). The energy-dispersive spectroscopy (EDS) confirms the presence of main components (Mn and O) (Fig. S1a), and the element mappings show co-existence of Mn and O elements in the structure of MnO$_2$-BSA (Fig. S1b), further indicating the successful construction of MnO$_2$-BSA NPs. Additionally, the X-ray photoelectron spectroscopy (XPS) shows +4 valence of Mn atoms in MnO$_2$-BSA NPs (Fig. S2), wherein the content of Mn elements is 21% in MnO$_2$-BSA according to the ICP-OES. MnO$_2$-BSA can react with H$_2$O$_2$ to produce •OH through a Fenton-like reaction with the help of HCO$_3^-$.

Methylene blue (MB) was selected as an indicator to assess the •OH generation since MB could be degraded by •OH [27, 28]. Apparently, the absorbance of MB sharply declines when they are incubated with the mixture of MnO$_2$-BSA, H$_2$O$_2$ and GSH. In contrast, H$_2$O$_2$ and MnO$_2$-BSA in the absence of GSH fail to significantly affect MB absorbance even though they are proceeded under the help of HCO$_3^-$ (Fig. 1d), suggesting poor chemical dynamic action. As the reaction time elapses, MB degradation is increased (Fig. 1e), and the MB degradation behavior displays an H$_2$O$_2$ concentration-dependent manner (Fig. 1f). The reaction rates under different pH values (PH = 5.0, 6.5 and 7.4) were also detected by the MB degradation method, and results show that the reaction rates at different pH values have no obvious difference, indicating the high efficiency of MnO$_2$-BSA-mediated CDT (Fig. 1g). Electron paramagnetic resonance (EPR) spectrometer that utilized
5,5-dimethyl-1-pyrroline N-oxide (DMPO) as the •OH capturing agent to confirm CDT occurrence and •OH production [18, 29]. The control group is disabled to produce •OH (Fig. 1h), while the group of MnO₂-BSA containing H₂O₂ and GSH generates massive •OH, as evidenced by the emergence of characteristic peaks of •OH. More importantly, radiolabelling stability assay shows that 211At-ATE-MnO₂-BSA radioimmunotherapy promoters are equipped with high stability in PBS and 10% FBS over 24 h (Fig. 1i).

**In vitro direct inhibition by the combined CDT and TAT ROS** has been documented to correlate with different biological activities [30–33], especially in which ROS could directly destroy tumor cells and activate immune responses [34]. As the CCK8 assay reveals, the low radioactive dose of 211At-ATE-MnO₂-BSA radioimmunotherapy promoters efficiently suppresses 4T1 cells and CT26 cells. Notably, as the radioactive dose of 211At-ATE-MnO₂-BSA just reaches 0.48 μCi, the cell viabilities of 4T1 and CT26 are dramatically decreased (Fig. 1i).
destroying DNA and killing tumor cells. To evaluate the DNA destruction caused by TAT, γ-H2AX that positively correlates with DNA damages was assessed by immunofluorescence staining [35]. It is found that the 211At-ATE-MnO2-BSA group shows the strongest red fluorescence signal and intensity, while the free 211At and MnO2-BSA receive few or no red fluorescence (Fig. S4). Comet assay was performed to further evaluate the DNA damages in each group, where DNA damages were assessed by the tail length of fluorescent DNA staining [36]. Results show that the cells treated with 211At-ATE-MnO2-BSA receive the most evident comet tails (Fig. S5). These results suggest that 211At in 211At-ATE-MnO2-BSA can promote ROS production for destroying DNA and killing tumor cells.

**In vivo combined CDT and TAT inhibit tumor progression**

Inspired by the excellent therapeutic results in vitro, we explored the distribution of 211At-ATE-MnO2-BSA radioimmunotherapy promoters in 4T1 tumor bearing mice and CT26 tumor bearing mice models, respectively. Compared to the free 211At group, the 211At-ATE-MnO2-BSA group exhibits high tumor retention and the accumulation in tumor remains high after 12 h post-injection (Fig. 2a and b), ensuring the subsequent anti-tumor outcomes. To further evaluate the therapeutic efficacy of astatine-211-labelled MnO2-BSA in vivo, the murine breast 4T1 tumors with poor immunogenicity were divided into four groups randomly (n=4), including: control, MnO2-BSA, free 211At (15 μCi) and 211At -ATE-MnO2-BSA (15 μCi). After 14 days post-treatment, the tumor volume in the control group grows rapidly. In contrast, the treatments in both MnO2-BSA group and free 211At group inhibit tumor growth to some certain extent via the GSH depletion-enhanced CDT and TAT, respectively. Once the two anti-tumor actions are integrated into 211At-ATE-MnO2-BSA radioimmunotherapy promoters, the most potent anti-tumor activity is reached, resulting in the largest inhibition rate of tumor growth (Fig. 2c and d, Table S1). Meanwhile, no negligible changes were found in the body weight after 211At-ATE-MnO2-BSA treatment, indicating good biocompatibility (Fig. 2e). Furthermore, to explore the mechanisms that cause the different therapeutic effects, hematoxylin–eosin (H&E) staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were performed. We find that 211At-ATE-MnO2-BSA radioimmunotherapy promoters acquires the highest cell damage/apoptosis, including chromatic agglutination, karyopyknosis, and nuclear fragmentation in hematoxylin–eosin (H&E) and brown stain in the TUNEL assay (Fig. 2f).

**The immune activation tests**

To explore the principles of the TAT and CDT combined effects in enhancing above anti-tumor outcomes, immune-related indexes were explored. It has been reported that radiotherapy could trigger immune responses by releasing tumor-associated antigens. Dendritic cells (DCs) played a critical role both in innate and adaptive immune responses through engulfing and processing antigens and presenting them to activate T cells [37]. Thus, the co-stimulatory molecules CD80/CD86 which are the representative markers for DCs maturation, are detected by flow cytometry (FCM) [38]. Tumor tissues were collected from CT26 tumor-bearing mice after 3 days post-various treatments (MnO2-BSA, free 211At, 211At -ATE-MnO2-BSA, n=3). Free 211At and 211At-ATE-MnO2-BSA could significantly promote the proportion of matured DCs, as compared to the untreated control group (Figs. 2g and S11). As a result, this result indicated that 211At labelled Mn-based radiosensitizer could serve as an immunostimulant to boost anti-tumor immune responses.

**Enhanced CDT-TAT-ICB tri-modal therapy for inhibiting metastasis**

In previous studies, the PD-L1 expression on 4T1 tumor cells was found to be too low to respond to anti-PD-L1 treatment. It has been documented that internal radioisotope therapy could regulate the expression of PD-L1 on tumors [39, 40]. Combining PD-L1 checkpoint blockade with internal radioisotope therapy will bring new hope for patients with metastases and relapse [41]. To validate the therapeutic efficiency of 211At-ATE-MnO2-BSA...
Fig. 2 (See legend on previous page.)
combined with PD-L1 blockade in metastasis tumors, the bilaterally 4T1-bearing mice or CT26-bearing mice were adopted. 4T1 (or CT26) cells inoculated in left flank of mouse were regarded as the primary tumor, the second tumor was inoculated in the right flank to mimic metastatic tumor. The experimental procedure is shown in Fig. 3a. For 4T1 tumors, we observe that the tumors on both sides in untreated group grow rapidly at an uncontrollable rate. Compared with untreated group, the anti-PD-L1 group delays the tumor growth, but all the mice die within 24 days, resulting in the low survival rate. Intriguingly, the tumor growths in 211At-ATE-MnO2-BSA group and 211At-ATE-MnO2-BSA plus anti-PD-L1 group are also obviously inhibited, and concurrently the survival time is significantly prolonged, as evidenced in Fig. 3b-d. Consistent with the 4T1 tumor model, 211At-ATE-MnO2-BSA plus anti-PD-L1 treatment not only completely destroys the local CT26 tumors, but also greatly inhibits the growth of distant tumors (Fig. 3e and f, and Figs. S7 and S8). Notably, the TAT/CDT/ICB tri-modal synergistic group shows a considerably-prolonged survival rate than other groups (Fig. 3g). As well, all the tumor-bearing mice have no abnormal body-weight changes in this synergistic group, and no pathological changes and no liver and kidney function changes are found in the major organs, indicating the high therapeutic biosafety of IRT/ICB treatment (Figs. S6, S9 and S10).

Mechanism of systematic antitumor immune responses

To understand the underlying mechanism of the antitumor effects triggered by 211At-ATE-MnO2-BSA plus anti-PD-L1, immune cells in the distant tumors were assessed on the 10th day after the first treatment on the bilaterally CT26 tumors-bearing mouse model. Cytotoxic T lymphocytes (CTLs) (CD3+CD8+CD62L-) cells are essential for the tumor immunotherapy [42]. Results show that the proportion of intratumoral CD8+ T cells is increased in the distant tumors after 10 days post-treatment with 211At-ATE-MnO2-BSA plus anti-PD-L1 (Fig. 4a and c), which is consistent with previous studies [23, 43]. Concurrently, immunosuppressive lymphocytes including regulatory T cells (Tregs) have no obvious changes in the distant tumors (Fig. 4b and d). Furthermore, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-γ) that are important markers of cellular antitumor immunity and involve in the cytotoxic functions of CTLs are increased significantly (Fig. 4e) [44]. These results suggest the activated immune responses by the synergistic treatment effects of TAT, CDT and ICB in such radioimmunotherapy promoters.

Long-term immune-memory effects for repressing relapse

As a hallmark of adaptive immunity, immunological memory response is able to protect organisms from the second attack of pathogen infection, including cancer cells [45, 46]. To evaluate whether the tri-modal TAT/CDT/ICB combined treatment could induce an immune memory effect, CT26 cells were inoculated 28 d on the opposite (left) side after removing the initial CT26 tumors (right) by this combination treatment, as illustrated in Fig. 5a. At the same time, five mice inoculated with equal numbers of cells on the left without treatment were set as the control group. The tumors in control group grow rapidly at an uncontrolled speed. In contrast, a remarkable and appealing result is obtained that no rechallenged tumor on the left side is detected in all mice after their initial tumors on the right side are completely inhibited by 211At-ATE-MnO2-BSA plus anti-PD-L1 therapy (Fig. 5b and d). Besides, no obvious changes are found in the body weight (Fig. 5c). Taken all together, these results clearly reveal that the long-term immune memory effect enables the treated mice to resist tumor relapse.

To explore the mechanisms of immune memory generated by the combined therapy, spleens were collected on day 15th day post-rechallenge, and the memory T cells were evaluated by flow cytometry. It is known that the memory T cells can be divided into central memory T cells (TCM, CD3+CD8+CD62L+CD44+) and effector memory T cells (TEM, CD3+CD8+CD62L−CD44+) [47]. TCM fails to provide protection at the beginning of antigen-stimulation, and they can exert the killing effects only if they undergo a series of processes such as expansion and differentiation [48]. Differing from TCM cells, TEM cells could instantly induce protection through secreting important cytokines such as TNF-α and IFN-γ after meeting the same pathogen, which are identified as the direct executor of immunotherapy [49]. Interestingly, the proportions of TEM in both CD8+ and CD4+ T cell populations are significantly increased after 211At-ATE-MnO2-BSA plus anti-PD-L1 therapy, whereas the percentage of TCM is decreased (Fig. 5e). Moreover, the level of IFN-γ was obviously up-regulated, suggesting the robust antitumor immune responses generated by the combination therapy strategy (Fig. 5f).
Fig. 3 (See legend on previous page.)
Discussion

It has been documented that IRT based on β-particles is widely used in clinics, which not only kills tumor cells through the direct killing effect, but also can elicit immune responses to attack the tumor cells to some extent [3]. However, it usually causes physiological toxicity and radiation resistance due to the existence of a hypoxic tumor microenvironment [4, 5]. Moreover, the low production efficiency of ROS induces poor immune responses, which is not sufficient to repress tumor metastasis and relapse.

In this report, α-particles with the advantages of high linear energy transfer (>50 keV/μm) were developed based on MnO₂-BSA, leading to more DNA double-strand injures and relative biological efficiency elevation with a lower radiation dose. The cyclotron-produced 211At address currently inadequate supplies of medically useful α-emitters. Thus, 211At is regarded to be the most suitable candidate for TAT, which is sufficient for labeling process, quality control, and medical application. In addition, the short half-life won’t cause medical problems by long-lived daughters of α-emitting radionuclide.
Fig. 5 TAT/CDT/ICB trimodal treatment for inhibiting tumor cell rechallenge. (a) Schematic illustration of the combination therapy to generate anticancer immune memory and inhibition of cancer recurrence. (b) Growth curves of the rechallenged tumors after different treatments. Data are mean ± s.d. (n = 5). (c) Body weight of balb-c mice. Data are expressed as mean ± SD (n = 5). (d) Photographs of 211At-ATE-MnO2-BSA + anti-PD-L1 cured mice and untreated mice receiving CT26 tumor cells. (e) Representative flow cytometric analysis images and corresponding quantification results of the percentage of central memory T cells (TCM) and effector memory T cells (TEM) of splenic lymphocytes of different groups 15 days after CT26 tumor cell rechallenge (n = 3). (f) Expression levels of serum cytokines including TNF-α and IFN-γ from mice after the secondary tumor rechallenge (n = 3). P values were calculated by t-test (*P<0.05, **P<0.01 and ***P<0.001)
CDT is an emerging therapeutic strategy by utilizing Fenton or Fenton-like reactions to modulate the immunogenic tumor microenvironment and enhance ICB. It was reported that Fe-based CDT could trigger tumor-associated antigens release and further allowed to be taken up and captured by DCs, leading to systemic immune responses. However, CDT alone also fails to sufficiently activate immune responses, and it usually requires combined therapy such as radiotherapy. Fortunately, MnO₂-BSA in our radioimmunotherapy promoters could trigger Fenton-like reactions to deplete H₂O₂ and GSH and realize redox balance disruption-enhanced CDT for producing ROS. The enhanced CDT synergized with TAT to activate robust immune responses to repress tumor progression including primary and distant tumors. ICB is widely used in a broad range of cancers, such as non-small cell lung cancer [50], clear cell renal cell carcinoma [51], breast cancer [52], melanoma [53], and head and neck cancer [54]. However, it seems to be effective in only 20% of cancer patients due to the ITM and immune-desert cold tumors with low mutation burdens, low neoantigen burden, and low level of effector T cells [16]. Inspiringly, besides activating systemic immune responses, the massive ROS production in the TAT/CDT combined therapy also favor ICB liberation, and they further united with ICB to significantly delay tumor growth and relapse via activating long-term immune memory effects on the challenge model, which means such radioimmunotherapy promoters could serve as tumor vaccines of non-small cell lung cancer, clear cell renal cell carcinoma, breast cancer, colon cancer, and others.

**Conclusions**

In summary, Mn-based radioimmunotherapy promoters with high radiolabeling stability were designed and developed to promote the therapeutic efficacy of ²¹¹At in vitro and in vivo through the TAT/CDT synergistic effects. It is noteworthy that such TAT-CDT could promote DC maturity and boost systematic anticancer immune responses. Besides, with the help of anti-PD-L1 blockade, distant tumors were obviously inhibited by cooperative TAT-CDT-ICB both in bilaterally 4T1 and CT26-bearing mice. The increasing of CD45⁺ leucocytes and CTL, and the reduction of Tregs as well as the rising cytokine secretion prove that the enhanced immunotherapy. Excitingly, the trimodal TAT/CDT/ICB combined therapy strategy could induce long-term immunological memory to resist tumor rechallenge owing to the generation of T memory cells. For clinical translation, this therapeutic modality might provide more opportunities for patients with metastatic tumors and prevent tumor relapse.

**Abbreviations**

TAT: Targeted alpha therapy; CDT: Chemodynamic therapy; BSA: Bovine serum albumin; DCs: Dendritic cells; RT: Radiotherapy; IRT: Internal radiotherapy; EBRT: External-beam radiotherapy; ICB: Immune checkpoint blocking; ATE: N-succinimidyl 3-trimethylstannyl-benzoate; ROS: Reactive oxygen species; TAA: Tumor-associated antigens; CTLs: Cytotoxic T lymphocytes; DLS: Dynamic light scattering; MB: Methylene blue; DMPO: 5,5-dimethyl-1-pyrroline N-oxide; HE: Hematoxylin–eosin; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling; FCM: Flow cytometry; Tregs: Regulatory T cells; TNF-α: Tumor necrosis factor-alpha; IFN-γ: Interferon-gamma; TCM: Central memory T cells; TEM: Effector memory T cells; MnCl₂; H₂O₂: Manganese chloride tetrahydrate; NaOH: Sodium hydroxide; FBS: Fetal bovine serum; CCK-8: Cell counting kit-8; μCi: Micro Curie.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40824-022-00290-6.

**Additional file 1.**

**Authors’ contributions**

These authors contributed equally to this work. J. Z., F. Y. and Y. Y. conceived this project; J. Z. and K. Z. designed the plans; J. Z., F. L., Y. Y., N. L., M. Z., H. Z., W. L., M. Y., S. Q. and X. F. performed the experiments; J. Z. and K. Z. analyzed the data and organized the figures; J. Z. wrote the paper and K. Z. revised this manuscript; and all authors commented on this manuscript. The author(s) read and approved the final manuscript.

**Funding**

This work was supported by National Natural Science Foundation of China (Grant No. 82071956, 82022033), Clinical Research Plan of SHDC (No.2020CR4065), National Key Research and Development Program of China (No.2016YFC0104303), the Shanghai Rising-Star Program (Grant No. 19QA1406800), Shanghai Talent Development Fund (No. 2019040).

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

All animals were provided by the animal center of Shanghai Tenth People's Hospital, and all animal experiments were approved by Animal Welfare Ethics Committee of Shanghai Tenth People's Hospital with an approval number (SHDSY-2021-3429-0746).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interest conflicts.

**Authors’ details**

1. Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China. 2. Institute of Nuclear Medicine, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People’s Republic of China. 3. Department of Medical Ultrasound and Central Laboratory, Ultrasound Research and Education Institute, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China. 4. Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, People’s Republic of China.

Received: 26 April 2022   Accepted: 28 August 2022

Published online: 08 September 2022
39. Pei P, Shen W, Zhou H, Sun Y, Zhong J, Liu T, et al. Radionuclide labeled gold nanoclusters boost effective anti-tumor immunity for augmented radio-immunotherapy of cancer. Nano Today. 2021;38. https://doi.org/10.1016/j.nantod.2021.101144.

40. Liang C, Chao Y, Yi X, Xu J, Feng L, Zhao Q, et al. Nanoparticle-mediated internal radioisotope therapy to locally increase the tumor vasculature permeability for synergistically improved cancer therapies. Biomaterials. 2019;197:368–79. https://doi.org/10.1016/j.biomaterials.2019.01.033.

41. Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, et al. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a (177) Lu-labeled ePD-L1 antibody. Theranostics. 2021;11(1):304–15. https://doi.org/10.7150/thno.45540.

42. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003;21:107–37. https://doi.org/10.1146/annurev.immunol.21.120601.140946.

43. Zhang K, Fang Y, He Y, Yin H, Guan X, Pu Y, et al. Extravascular gelation shrinkage-derived internal stress enables tumor starvation therapy with suppressed metastasis and recurrence. Nat Commun. 2019;10(1):3380. https://doi.org/10.1038/s41467-019-13115-3.

44. Chen Q, Chen J, Yang Z, Xu J, Xu L, Liang C, et al. Nanoparticle-enhanced radiotherapy to trigger robust Cancer immunotherapy. Adv Mater. 2019;31(10):e1802228. https://doi.org/10.1002/adma.201802228.

45. Teixeiro E, Daniels MA, Hamilton SE, Schrum AG, Bragado R, Jameson SC, et al. Different T cell receptor signals determine CD8+ memory versus effector development. Science. 2009;323(5913):502–5. https://doi.org/10.1126/science.1163612.

46. Kirnjo I, Qin J, Tan S-Y, Wellard CJ, Mrass P, Ritchie W, et al. Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation. Nat Commun. 2015;6(1):6301. https://doi.org/10.1038/ncomms7301.

47. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–12. https://doi.org/10.1038/44385.

48. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2005;6(3):225–34. https://doi.org/10.1038/nri1489.

49. Kaech SM, Caule W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. 2012;12(11):749–61. https://doi.org/10.1038/nri3307.

50. Martinez-Usatorre A, Kadioglu E, Borvin G, Canciuruco C, Guichard A, Torchia B, et al. Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Sci Transl Med. 2021;13(606):eaabd1616. https://doi.org/10.1126/scitranslmed.abc1616.

51. Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021;39(5):632–648.e638. https://doi.org/10.1016/j.ccell.2021.02.013.

52. Bassez A, Vos H, Van Dyck L, Floris G, Arijs I, Desmedt C, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27(5):820–32. https://doi.org/10.1038/s41591-021-01323-8.

53. Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, et al. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nat Med. 2020;26(5):781–91. https://doi.org/10.1038/s41591-020-0819-3.

54. Zhou L, Zeng Z, Eglolf AM, Zhang F, Guo F, Campbell KM, et al. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. J Immunother Cancer. 2022;10(1):e004034. https://doi.org/10.1136/jitc-2021-004034.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.